|
A machine learning-based approach for the inference of immunotherapy biomarker status in lung adenocarcinoma from hematoxylin and eosin (H&E) histopathology images. |
|
|
|
Stock and Other Ownership Interests - Bristol-Myers Squibb; Verily |
Patents, Royalties, Other Intellectual Property - Celverum; Verily |
Travel, Accommodations, Expenses - Verily |
|
|
|
Stock and Other Ownership Interests - Verily |
Patents, Royalties, Other Intellectual Property - Verily |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Google |
Research Funding - Google |
Patents, Royalties, Other Intellectual Property - Google |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Verily |
Travel, Accommodations, Expenses - Verily |
|
|
|
Stock and Other Ownership Interests - Verily |
|
|
Employment - Agilent; Premier Pathology Laboratories, Inc.; Verily |
Leadership - Premier Pathology Laboratories, Inc. |
Stock and Other Ownership Interests - Agilent; Premier Pathology Laboratories, Inc. |
Travel, Accommodations, Expenses - Merck |
|
|
|
Stock and Other Ownership Interests - Verily |